No off-target reactivity of JCHAIN-negative heathy cell subsets was apparent, but on-target/off-tumor reactivity of JCHAIN expressing B cells revealed that Jchain TCR gene therapy would likely result in depletion of the healthy B-cell compartment in vivo. Here, JCHAIN is linked to neoplasm.